Abstract
Limited access to human islets has prompted the development of human beta cell models. The human beta cell lines EndoC-βH1 and EndoC-βH2 are increasingly used by the research community. However, little is known of their electrophysiological and secretory properties. Here, we monitored parameters that constitute the glucose-triggering pathway of insulin release. Both cell lines respond to glucose (6 and 20 mM) with 2- to 3-fold stimulation of insulin secretion which correlated with an elevation of [Ca2+]i, membrane depolarisation and increased action potential firing. Similar to human primary beta cells, KATP channel activity is low at 1 mM glucose and is further reduced upon increasing glucose concentration; an effect that was mimicked by the KATP channel blocker tolbutamide. The upstroke of the action potentials reflects the activation of Ca2+ channels with some small contribution of TTX-sensitive Na+ channels. The repolarisation involves activation of voltage-gated Kv2.2 channels and large-conductance Ca2+-activated K+ channels. Exocytosis presented a similar kinetics to human primary beta cells. The ultrastructure of these cells shows insulin vesicles composed of an electron-dense core surrounded by a thin clear halo. We conclude that the EndoC-βH1 and -βH2 cells share many features of primary human β-cells and thus represent a useful experimental model.
| Original language | English |
|---|---|
| Article number | 16994 |
| Journal | Scientific Reports |
| Volume | 8 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published (in print/issue) - 1 Dec 2018 |
Funding
MvdB was supported by a Novo Nordisk postdoctoral fellowship run in partnership with the University of Oxford. A.L.G. is a Wellcome Trust Senior Fellow in Basic Biomedical Science. This work was funded by the Wellcome Trust (095531/Z11/Z [P.R.]; 095101, 200837, and 106130 [A.L.G]), Medical Research Council (MR/ L020149/1) [A.L.G., P.R.], the European Union Horizon 2020 Programme (T2D Systems)[A.L.G], the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)[A.L.G. and P.R] as well as the Swedish Research Council [P.R.]. The views expressed are those of the author(s) and not necassarily those of the NHS or the Department of Health.